Workflow
Lishengpharma(002393)
icon
Search documents
力生制药(002393) - 天津力生制药股份有限公司募集资金2025半年度存放与使用情况的专项报告
2025-08-21 10:31
天津力生制药股份有限公司关于募集资金 2025 半年度存放与使用情况的专项报告 2025 年 1 月 1 日至 2025 年 6 月 30 日(本专项报告除特别注明外,均以人民币元列示) 天津力生制药股份有限公司 关于募集资金2025半年度存放与使用情况的专项报告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整,没有虚假记载、 误导性陈述或重大遗漏。 一、 募集资金基本情况 (一) 募集资金金额及到位时间 经中国证券监督管理委员会《关于核准天津力生制药股份有限公司首次公开发行股 票的批复》(证监许可[2010]371 号)文核准,公司首次向社会公开发行人民币普通 股(A 股)4,600 万股,每股面值 1.00 元,发行价格为 45 元/股,共募集资金总额 2,070,000,000.00 元,扣除各项发行费用 62,301,336.76 元,实际募集资金净额为 2,007,698,663.24 元。上述募集资金已于 2010 年 4 月 16 日到位。 (二) 募集资金以前年度使用金额 2024 年度本公司实际使用募集资金 5,259,705.50 元,用于支付公司扩建项目尾款。 2024 年度收 ...
力生制药(002393) - 关于召开2025年第二次临时股东会的通知
2025-08-21 10:31
证券代码:002393 证券简称:力生制药 公告编号:2025-054 天津力生制药股份有限公司 关于召开2025年第二次临时股东会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确和完整,没有虚假记载、 误导性陈述或重大遗漏。 天津力生制药股份有限公司(以下简称"公司"或"本公司")第七届董事会第五十二次审 议的相关事宜,按照公司章程规定,董事会审议通过后,须提交股东会进行审议。2025年第 二次临时股东会的有关事宜如下: 一、召开会议的基本情况 7、会议召开方式:本次股东会采取现场投票与网络投票相结合的方式 公司将通过深圳证券交易所交易系统和互联网投票系统(http://wltp.cninfo.com.cn)向 1、股东会届次:2025年第二次临时股东会 2、会议召集人:公司董事会,本次股东会经公司第七届董事会第五十二次会议决议召 开。 3、会议召集、召开的合法、合规性:本次股东会会议召集、召开符合有关法律、行政 法规、部门规章、规范性文件和公司章程的规定。 4、会议召开时间: 现场会议召开时间:2025年09月08日(星期一)下午2:40开始 网络投票时间为:2025年09月08日,其中通过深圳 ...
力生制药(002393) - 监事会关于调整限制性股票激励计划回购价格暨回购注销部分激励对象已获授但尚未解除限售的限制性股票的核查意见
2025-08-21 10:30
监事会关于调整限制性股票激励计划回购价格暨回购注 销部分激励对象已获授但尚未解除限售的限制性股票的 核查意见 证券代码:002393 证券简称:力生制药 公告编号:2025-057 天津力生制药股份有限公司 因此,我们一致同意对 2022 年限制性股票激励计划授予的限制性股票(含预留部分) 回购价格进行调整,首次授予限制性股票的回购价格由 9.11 元/股调整为 8.76 元/股,预 留授予部分的回购价格由 8.49 元/股调整为 8.14 元/股。 公司本次回购注销部分激励对象已获授但尚未解除限售的限制性股票的原因、数量、 回购价格及资金来源合法有效,符合《公司法》《管理办法》等法律法规及《公司章程》 《2022 年激励计划》等规定,并履行了必要决策程序。公司本次回购注销部分激励对象 已获授但尚未解除限售的限制性股票程序合法、合规,不存在损害公司及全体股东利益的 情形、不会对公司的财务状况和经营成果产生重大影响。 本公司及董事会全体成员保证信息披露的内容真实、准确和完整,没有虚假记载、 误导性陈述或重大遗漏。 根据《中华人民共和国公司法》(以下简称"《公司法》")《中华人民共和国证券 法》《上市公司股权激励 ...
力生制药(002393) - 半年报监事会决议公告
2025-08-21 10:30
第七届监事会第四十三次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整,没有虚假记载、 误导性陈述或重大遗漏。 一、监事会会议召开情况 天津力生制药股份有限公司(以下简称"公司"或"本公司")于2025年8月13日以书面方式 发出召开第七届监事会第四十三次会议的通知,会议于2025年8月20日以通讯表决方式召 开。会议应参加的监事3名,实际参加的监事3名,符合《公司法》及《公司章程》的规定。 二、监事会会议审议情况 证券代码:002393 证券简称:力生制药 公告编号:2025-050 天津力生制药股份有限公司 2025 年半年度报告及摘要详见巨潮资讯网(www.cninfo.com.cn)、中国证券报和证 券时报。 2、会议以3票同意、0票反对、0票弃权的表决结果,审议通过了《关于2025年半年 度募集资金存放与实际使用专项报告的议案》; 3、会议以3票同意、0票反对、0票弃权的表决结果,审议通过了《关于公司参与设 立产业医药基金暨关联交易的议案》; 监事会认为:公司本次参与设立产业医药基金暨关联交易事项符合公司总体战略规划, 不存在损害公司及股东利益的情形。公司董事会在审议关联交易事 ...
力生制药(002393) - 半年报董事会决议公告
2025-08-21 10:30
证券代码:002393 证券简称:力生制药 公告编号:2025-049 天津力生制药股份有限公司 第七届董事会第五十二次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整,没有虚假记载、 误导性陈述或重大遗漏。 一、董事会会议召开情况 天津力生制药股份有限公司(以下简称"公司"或"本公司")于2025年08月13日以书面方式 发出召开第七届董事会第五十二次会议的通知,会议于2025年08月20日以通讯表决方式召 开。会议应参加的董事9名,实际参加的董事9名。符合《公司法》及《公司章程》的规定。 二、董事会会议审议情况 1、会议以9票同意、0票反对、0票弃权的表决结果,审议通过了《关于2025年半年度报 告全文及摘要的议案》; 2025 年半年度报告及摘要详见巨潮资讯网(www.cninfo.com.cn)、中国证券报和证券 时报。 2、会议以9票同意、0票反对、0票弃权的表决结果,审议通过了《关于2025年半年度募 集资金存放与实际使用专项报告的议案》; 公 司 独 立 董 事 专 门 会 议 对 本 议 案 发 表 了 意 见 , 具 体 内 容 详 见 巨 潮 资 讯 网 (www.c ...
力生制药(002393) - 2025 Q2 - 季度财报
2025-08-21 10:25
天津力生制药股份有限公司 2025 年半年度报告全文 天津力生制药股份有限公司 2025 年半年度报告 国家医疗体制改革持续深化,实施带量采购、一致性评价、医保控费、两 票制、安全环保升级等政策,给公司经营发展带来挑战,对药品研发、生 产、销售产生较大影响。 (二)研发及转型风险 2025 年 8 月 天津力生制药股份有限公司 2025 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的 真实、准确、完整,不存在虚假记载、误导性陈述或者重大遗漏,并承担个 别和连带的法律责任。 公司负责人张平、主管会计工作负责人王家颖及会计机构负责人(会计主 管人员)高峻声明:保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本次半年报的董事会会议。 本报告中涉及的未来发展陈述,属于计划性事项,不构成公司对投资者的 实质承诺,敬请投资者注意投资风险。 (一)行业政策变化风险 公司致力于通过研发创新促进公司的转型升级,由于医药行业新品研发周 期长、投入大、不确定性强,公司会面临研发不成功或研发效果不及预期的 风险。 (三)生产要素成本不断上涨的风险 ...
短线防风险 20只个股短期均线现死叉
Market Overview - The Shanghai Composite Index is at 3639.18 points with a change of 0.11% [1] - The total trading volume of A-shares is 832.786 billion yuan [1] Stocks with Death Cross - 20 A-shares have seen their 5-day moving average cross below the 10-day moving average [1] - Notable stocks include: - Angli (002940) with a 5-day moving average of 56.59 yuan, down 1.78% from the 10-day moving average [1] - Chengdu Xian Dao (688222) with a 5-day moving average of 23.11 yuan, down 1.64% [1] - Sai Sheng Pharmaceutical (300485) with a 5-day moving average of 14.83 yuan, down 1.40% [1] Additional Stock Data - Other stocks with significant moving average changes include: - Zhi Xiang (688443) with a 5-day moving average of 33.34 yuan, down 0.85% [1] - Changshan Pharmaceutical (300255) with a 5-day moving average of 41.59 yuan, down 0.68% [1] - Zhi Zheng (603991) with a 5-day moving average of 72.69 yuan, down 0.40% [1] Performance Summary - The performance of various stocks shows a mix of slight gains and losses, with some stocks like Angli and Chengdu Xian Dao experiencing notable declines in their moving averages [1][2] - The overall market sentiment appears cautious, reflected in the trading volumes and the number of stocks showing bearish signals [1]
创新药十年蝶变!从跟跑到领跑,普通人的财富密码藏在哪?
券商中国· 2025-08-10 23:30
Core Viewpoint - The investment value of innovative drugs is not a short-term pulse but a long-term industrial dividend, with optimal solutions for sharing this dividend through index tools in golden tracks [1] Group 1: Performance of Innovative Drug Indices - Since July, the National Index for Hong Kong Stock Connect Innovative Drugs and the China Securities Innovative Drug Industry Index have reached new highs, with year-to-date increases of 106.7% and 32.3% respectively as of July 31 [2] - The impressive performance of these indices reflects a decade-long transformation of China's innovative drug industry from "follower" to "leader" [2] - Recent inflows into ETFs tracking innovative drug indices have been significant, with a net inflow of 4.26 billion yuan from August 4 to August 8 and over 16 billion yuan since June [2] Group 2: Index Adjustments and Sensitivity - The recent upgrade of the Hong Kong Stock Innovative Drug Index aims to enhance its focus by excluding CXO companies and increasing adjustment frequency from semi-annual to quarterly, effective August 12 [3][4] - This adjustment allows the index to better capture the core drivers of the innovative drug industry, focusing on pharmaceutical companies that lead drug development and hold key patents [3] - The increased adjustment frequency enhances the index's sensitivity, enabling it to quickly identify emerging growth companies in a rapidly evolving market [4] Group 3: Policy Support for Innovative Drugs - The innovative drug industry has received significant policy support this year, with the State Council's 2025 strategic goal to create a globally competitive innovation ecosystem [5] - Multiple regulatory bodies have introduced supportive measures, including optimizing review processes and reopening IPO channels for unprofitable companies [6] - The 2024 medical insurance fund expenditure on innovative drugs is projected to be 3.9 times that of 2020, with an annual growth rate of 40% [7] Group 4: Market Dynamics and Future Outlook - By the end of 2024, China is expected to have 3,575 original innovative drugs in clinical trials, surpassing the U.S. and becoming the global leader [7] - The proportion of first-in-class (FIC) drugs has increased from less than 10% in 2015 to 24% in 2024, indicating a significant enhancement in original innovation capabilities [7] - The innovative drug market in China currently accounts for less than 10% of the total pharmaceutical market, indicating substantial growth potential compared to over 20% in other G20 countries [9] Group 5: Investment Opportunities in Innovative Drugs - The China Securities Innovative Drug Industry Index has shown a year-to-date increase of 32.3%, with significant upside potential remaining [8] - The long-term growth of the innovative drug market is supported by an aging population and increasing demand for treatments for chronic diseases and rare diseases [8] - Investing in ETFs that track the innovative drug sector provides a way to mitigate risks associated with individual stock investments while capitalizing on overall industry growth [9]
医药生物行业周报:集采新规促行业健康发展-20250722
East Money Securities· 2025-07-22 12:09
Investment Rating - The report maintains a "Strong Buy" rating for the pharmaceutical industry, indicating a positive outlook for investment opportunities [3]. Core Insights - The new centralized procurement regulations emphasize "stability in clinical use, quality assurance, prevention of collusion, and countering excessive competition," which are expected to promote the long-term healthy development of the industry [2][32]. - The report suggests focusing on recently launched innovative products, high-quality raw material suppliers, and key products that have passed the consistency evaluation for generic drugs [2][32]. Summary by Sections Market Review - The pharmaceutical and biotechnology index increased by 4% this week, outperforming the CSI 300 index by 2.91 percentage points, ranking second in industry performance [11]. - Year-to-date, the pharmaceutical and biotechnology index has risen by 16.59%, also surpassing the CSI 300 index by 13.45 percentage points [11]. - The chemical pharmaceutical sector showed the highest growth this week at 6.86%, while traditional Chinese medicine had the lowest decline at 0.88% [16][18]. Individual Stock Performance - In the A-share market, 397 out of 474 pharmaceutical stocks rose, with the top five performers being: - Borui Pharmaceutical (+42.35%) - Lisheng Pharmaceutical (+41.68%) - Nanxin Pharmaceutical (+34.95%) - Aosai Kang (+32.77%) - Yipin Hong (+32.13%) [22]. - In the Hong Kong market, 96 out of 106 pharmaceutical stocks increased, with the top performers including: - Clover Biopharma-B (+63.79%) - Lepu Biopharma-B (+62.04%) - Deqi Pharmaceutical-B (+47.04%) [25]. Industry News and Policies - The 11th batch of national centralized drug procurement was officially launched, including 55 varieties across various therapeutic areas, focusing on clinical needs and market realities [28]. - The new procurement rules are more refined, requiring production experience and quality control capabilities from manufacturers, which will help ensure drug quality and promote industry standardization [28]. - The establishment of the "Commercial Insurance Innovative Drug Directory" marks a significant step in building a multi-tiered medical security system, providing new economic support for innovative drug development [28]. Key Company Announcements - Heng Rui Pharmaceutical reported positive results from its GLP-1/GIP dual receptor agonist HRS9531 in a Phase III weight loss study, with an average weight reduction of 19.2% in the treatment group [29][31]. - The report highlights various corporate actions, including stock incentive plans and capital increases by several companies, indicating active corporate governance and strategic investments in the sector [36].
新股发行及今日交易提示-20250722
HWABAO SECURITIES· 2025-07-22 08:03
New Stock Issuance - New stock issued by Dingjia Precision at a price of 11.16 on July 22, 2025[1] - ST Kelly's tender offer period is from July 17 to August 15, 2025[1] - ST Zitian and other companies have also announced new stock issuances[1] Market Alerts - Significant abnormal fluctuations reported for several stocks including Guangshengtang and Huayin Power[1] - Multiple companies have disclosed announcements regarding stock performance and market activities[1] - The report includes links to detailed announcements for various stocks, indicating ongoing market monitoring[1]